All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer
- 366 Downloads
To evaluate the efficacy and safety of an all-oral vinorelbine and capecitabine combination therapy in anthracycline- ± taxane-pretreated HER2/Neu-negative metastatic breast cancer (MBC).
A phase 2 trial including women >18 years with HER2/Neu-negative MBC previously exposed to anthracycline- ± taxane-based chemotherapy in the adjuvant or neoadjuvant setting. Enrolled patients received oral vinorelbine 60 mg/m2 on days 1 and 8 and oral capecitabine 1,000 mg/m2 twice daily on days 1–14 on a 3 weekly schedule. Patients with progressive disease after 3 cycles discontinued the study, while the remaining patients continued treatment for a maximum of 6 cycles.
From January 2007 to March 2011, 30 patients were enrolled in this study (median age 47 years). In the 28 evaluable patients, the overall response rate was 57.1 % (95 % CI 30–67 %), including 3 complete (10.7 %) and 13 partial (46.4 %) responses. Six (21.4 %) patients suffered from disease progression. With a median follow-up time of 13 months, the median time to disease progression was 8.6 months (95 % CI 6.2–10.6 months) and the median survival time was 27.2 months. Treatment-related adverse events were manageable, and no World Health Organization grade 4 toxicities were noted. Neutropenia observed in 6 (21.4 %) patients was the main grade 3 toxicity. Grade 3 nausea and vomiting were reported in 2 (7.1 %) and 3 (10.7 %) patients, respectively. Two (7.1 %) patients developed grade 3 hand and foot syndrome.
These results show that the combination of oral vinorelbine and capecitabine is an effective and well-tolerated first-line regimen for HER2/Neu-negative MBC patients pretreated with anthracyclines ± taxanes.
KeywordsOral therapy First-line chemotherapy Metastatic breast cancer HER2/Neu-negative
Conflict of interest
None to disclose.
- 3.Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137–2150. doi: 10.1200/JCO.2005.05.2308 PubMedCrossRefGoogle Scholar
- 7.Henderson IC (2011) Can we abandon anthracyclines for early breast cancer patients? Oncology (Williston Park) 25(2):115–124, 127Google Scholar
- 8.Jones A, O’Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V (2010) Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 65(4):755–763. doi: 10.1007/s00280-009-1081-y PubMedCrossRefGoogle Scholar
- 12.Nole F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, Fougeray R, Brandely M, Goldhirsch A (2009) Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 64(4):673–680. doi: 10.1007/s00280-008-0915-3 PubMedCrossRefGoogle Scholar
- 13.Sawada N, Fujimoto-Ouchi F, Ishikawa T (2002) Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models [abstract 5388]. Proc Am Assoc Cancer Res 43:1088aGoogle Scholar
- 20.Estevez LG, Batista N, Sanchez-Rovira P, Velasco A, Provencio M, Leon A, Domine M, Cruz J, Rodriguez M (2008) A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 8(2):149–154. doi: 10.3816/CBC.2008.n.015 PubMedCrossRefGoogle Scholar
- 22.Mangino P, Taft B, Djulbegovic B (1997) Criteria for grading toxicity. In: Djulbegovic B, Sullivan DM (eds) Decision making in oncology: evidence-based management, 1st edn. Churchill Livingstone, New York, pp 454–468Google Scholar
- 23.Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38(3):349–358PubMedCrossRefGoogle Scholar
- 24.Lorusso V, Spada M, Giampaglia M, Misino A, Calabrese R, Latorre A, Monticelli G, Guida M, Sambiasi D, Colucci G (2006) Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell’Italia Meridionale). Ann Oncol 17(Suppl 7):15–17. doi: 10.1093/annonc/mdl942 Google Scholar
- 25.Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Conte PF, Majois F, Espie M, Morand M, Vaissiere N, Villanova G (2009) All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. Br J Cancer 101(2):232–237. doi: 10.1038/sj.bjc.6605156 PubMedCrossRefGoogle Scholar
- 26.Delcambre C, Veyret C, Levy C, Switsers O (2005) A phase I/II study of capecitabine combined with oral vinorelbine as first or second line therapy in locally advanced or metastatic breast cancer [abstract 1081]. Breast Cancer Res Treat 94:S67Google Scholar
- 27.Campone M, Dobrovolskaya N, Tjulandin S, Chen SC, Fourie SJ, Mefti F, Konstantinova M, Lefresne F, Meheust N, Jassem J (2011) Final results of a three-arm randomised phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines. Abstract presented at the CTRC-AACR 2011 San Antonio Breast Cancer SymposiumGoogle Scholar
- 28.Gampenrieder SP, Bartsch R, Matzneller P, Pluschnig U, Dubsky P, Gnant MX, Zielinski CC, Steger GG (2010) Capecitabine and vinorelbine as an all-oral chemotherapy in HER2-negative locally advanced and metastatic breast cancer. Breast Care (Basel) 5(3):158–162. doi: 10.1159/000314214 CrossRefGoogle Scholar
- 30.Rousseau F, Retornaz F, Joly F, Esterni B, Abadie-Lacourtoisie S, Fargeot P, Luporsi E, Servent V, Laguerre B, Brain E, Geneve J (2010) Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: a multicentre pilot study of the French geriatric oncology group (GERICO). Crit Rev Oncol Hematol 76(1):71–78. doi: 10.1016/j.critrevonc.2009.12.003 PubMedCrossRefGoogle Scholar